PainReform Ltd. (PRFX)

Last Closing Price: 2.31 (2024-03-01)

Company Description

PainReform a clinical stage specialty pharmaceutical company. It engages in the development of products for the treatment of pain. The company's product pipeline includes PRF-110, a product based on local anesthetic ropivacaine, which is in clinical stage. PainReform based in Herzeliya, Israel.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-9.34M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.50
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) --
Current Ratio (Most Recent Fiscal Quarter) 4.07
Quick Ratio (Most Recent Fiscal Quarter) 4.07
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.65
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Common Shares Outstanding 1.56M
Free Float 1.02M
Market Capitalization $3.60M
Average Volume (Last 20 Days) 0.02M
Beta (Past 60 Months) 0.53
Percentage Held By Insiders (Latest Annual Proxy Report) 34.40%
Percentage Held By Institutions (Latest 13F Reports) 9.50%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%